Privia Health Group (NASDAQ:PRVA) Upgraded by Zacks Research to “Hold” Rating

Privia Health Group (NASDAQ:PRVA) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

Other analysts have also recently issued reports about the company. Weiss Ratings raised Privia Health Group from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 2nd. Citigroup reissued a “buy” rating on shares of Privia Health Group in a research report on Thursday, July 23rd. Evercore set a $26.00 target price on Privia Health Group in a research note on Wednesday, April 8th. Barclays dropped their price target on Privia Health Group from $25.00 to $24.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 26th. Finally, Canaccord Genuity Group reduced their price target on Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Eleven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $31.15.

Privia Health Group Price Performance

Shares of NASDAQ PRVA opened at $22.00 on Wednesday. Privia Health Group has a 1 year low of $19.08 and a 1 year high of $28.82. The stock has a market capitalization of $2.77 billion, a P/E ratio of 137.51, a P/E/G ratio of 1.90 and a beta of 0.85. The company’s 50-day moving average is $24.61 and its 200 day moving average is $23.35.

Insider Buying and Selling

In related news, CFO David Mountcastle sold 24,734 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $27.50, for a total transaction of $680,185.00. Following the sale, the chief financial officer directly owned 186,728 shares of the company’s stock, valued at approximately $5,135,020. This represents a 11.70% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Parth Mehrotra sold 105,439 shares of Privia Health Group stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $22.55, for a total transaction of $2,377,649.45. Following the completion of the transaction, the chief executive officer directly owned 450,004 shares of the company’s stock, valued at $10,147,590.20. This trade represents a 18.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 452,357 shares of company stock worth $11,436,655 in the last quarter. Corporate insiders own 5.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of PRVA. GAMMA Investing LLC increased its stake in Privia Health Group by 14.0% during the second quarter. GAMMA Investing LLC now owns 4,819 shares of the company’s stock worth $124,000 after acquiring an additional 592 shares during the last quarter. State of Alaska Department of Revenue lifted its stake in shares of Privia Health Group by 1.3% in the 4th quarter. State of Alaska Department of Revenue now owns 65,747 shares of the company’s stock valued at $1,558,000 after purchasing an additional 823 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in shares of Privia Health Group by 8.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 10,361 shares of the company’s stock worth $213,000 after purchasing an additional 840 shares during the period. ProShare Advisors LLC boosted its holdings in shares of Privia Health Group by 4.1% in the 4th quarter. ProShare Advisors LLC now owns 22,576 shares of the company’s stock worth $535,000 after purchasing an additional 898 shares during the period. Finally, Vanguard Personalized Indexing Management LLC increased its position in shares of Privia Health Group by 5.9% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 16,250 shares of the company’s stock valued at $385,000 after purchasing an additional 903 shares during the last quarter. 94.48% of the stock is owned by institutional investors.

Key Headlines Impacting Privia Health Group

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Raised 2026 outlook: Management increased full-year guidance for attributed lives to 1.625–1.650 million, practice collections to the high end of $3.65–$3.75 billion, GAAP revenue to the high end of $2.35–$2.45 billion, and adjusted EBITDA to $145–$155 million. It also expects approximately 70%–80% of adjusted EBITDA to convert to free cash flow. Privia Health Reports Strong Second Quarter and Year-to-Date 2026 Results
• Positive Sentiment: Strong quarterly growth: Q2 revenue rose 21.4% year over year to $632.6 million, exceeding the $597.3 million consensus. Adjusted EPS was $0.19 versus the $0.07 analyst estimate, while net income increased to $9.0 million from $2.7 million. Privia Health Q2 Earnings Report
• Positive Sentiment: Operating momentum improved: Implemented providers grew 10.1% to 5,644, value-based-care attributed lives increased 19.2% to 1.647 million, and adjusted EBITDA climbed 29.1% to $37.4 million. Adjusted EBITDA margin expanded to 28.3% from 25.2%.
• Neutral Sentiment: Analyst comparisons are complicated by differing definitions: GAAP diluted EPS was $0.07, while adjusted EPS was $0.19. The adjusted figure benefited from add-backs, including $19.4 million of non-cash stock compensation expense.
• Negative Sentiment: Cash-flow concerns: Privia used $48.4 million in operating cash during the first half, largely because accounts receivable increased by $172.4 million. Cash declined to $412.2 million from $479.7 million at year-end.
• Negative Sentiment: PRVA’s valuation remains demanding, with a reported price-to-earnings ratio near 150. Heavy insider selling cited in recent data may also weigh on sentiment, even though the company’s operating results and outlook improved.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.